• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Which biologic agents increase perioperative complications in patients with inflammatory bowel disease?哪些生物制剂会增加炎症性肠病患者的围手术期并发症？
Intest Res. 2022 Jan;20(1):1-2. doi: 10.5217/ir.2021.00170. Epub 2022 Jan 26.
2
Exposure to biologic therapy and associated maternal and neonatal outcomes in pregnancies complicated by inflammatory bowel disease.炎症性肠病孕妇中生物治疗的暴露及其母婴结局。
Am J Obstet Gynecol MFM. 2022 Jan;4(1):100518. doi: 10.1016/j.ajogmf.2021.100518. Epub 2021 Oct 22.
3
Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn's disease).优化炎症性肠病（溃疡性结肠炎和克罗恩病）的生物疗法。
Curr Gastroenterol Rep. 2009 Dec;11(6):504-8. doi: 10.1007/s11894-009-0076-5.
4
Patterns of biologic agent use in older males with inflammatory diseases: an institution-focused, observational post-marketing study.老年男性炎症性疾病患者中生物制剂的使用模式：一项以机构为中心、观察性的上市后研究。
Drugs Aging. 2009;26(7):607-15. doi: 10.2165/11316350-000000000-00000.
5
Treatment With Biologic Agents Has Not Reduced Surgeries Among Patients With Crohn's Disease With Short Bowel Syndrome.生物制剂治疗并未减少短肠综合征克罗恩病患者的手术次数。
Clin Gastroenterol Hepatol. 2017 Dec;15(12):1908-1914.e2. doi: 10.1016/j.cgh.2017.06.040. Epub 2017 Jun 27.
6
Inflammatory bowel disease surgery in the biologic therapy era.生物治疗时代的炎症性肠病手术。
Curr Opin Gastroenterol. 2012 Jul;28(4):349-53. doi: 10.1097/MOG.0b013e328354d832.
7
Safety and Efficacy of Biologic Agents for the Management of Inflammatory Bowel Disease After Liver Transplantation.生物制剂在肝移植后治疗炎症性肠病中的安全性和疗效。
Pharmacotherapy. 2017 Dec;37(12):1578-1585. doi: 10.1002/phar.2036. Epub 2017 Nov 21.
8
Vedolizumab in the Perioperative Management of Inflammatory Bowel Disease.维多利珠单抗在炎症性肠病围手术期的应用。
Curr Drug Targets. 2019;20(13):1317-1322. doi: 10.2174/1389450120666190325130142.
9
The Effect of Biologics on Postoperative Complications in Children With Inflammatory Bowel Disease and Bowel Resection.生物制剂对炎症性肠病和肠切除术后儿童术后并发症的影响。
J Pediatr Gastroenterol Nutr. 2019 Mar;68(3):334-338. doi: 10.1097/MPG.0000000000002159.
10
Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors.在接受白细胞介素-17A 或磷酸二酯酶 4 抑制剂治疗的其他慢性炎症性疾病患者中，炎症性肠病的真实世界发病率。
Curr Med Res Opin. 2019 Oct;35(10):1751-1759. doi: 10.1080/03007995.2019.1620713. Epub 2019 Jun 6.

引用本文的文献

1
Vaccination strategies for Korean patients with inflammatory bowel disease.韩国炎症性肠病患者的疫苗接种策略。
Korean J Intern Med. 2022 Sep;37(5):920-930. doi: 10.3904/kjim.2022.149. Epub 2022 Aug 8.

本文引用的文献

1
Natural history of inflammatory bowel disease: a comparison between the East and the West.炎症性肠病的自然史：东西方比较
Intest Res. 2022 Oct;20(4):418-430. doi: 10.5217/ir.2021.00104. Epub 2021 Dec 2.
2
Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation.接受不同生物制剂的炎症性肠病患者不良事件的发生率比较：回顾性长期评估
Intest Res. 2022 Jan;20(1):114-123. doi: 10.5217/ir.2021.00037. Epub 2021 Aug 4.
3
Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study.队列研究：维多珠单抗不会增加炎症性肠病患者围手术期的手术并发症。
Intest Res. 2022 Jan;20(1):72-77. doi: 10.5217/ir.2020.00117. Epub 2021 Feb 3.
4
Biologics and surgical outcomes in Crohn's disease: is there a direct relationship?克罗恩病的生物制剂与手术结局：二者存在直接关联吗？
Therap Adv Gastroenterol. 2020 Jul 16;13:1756284820931738. doi: 10.1177/1756284820931738. eCollection 2020.
5
Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study.抗 TNF 治疗的引入并未使炎症性肠病的住院率和肠切除术率如预期般下降：一项基于人群的中断时间序列研究。
Gut. 2020 Feb;69(2):274-282. doi: 10.1136/gutjnl-2019-318440. Epub 2019 Jun 12.
6
Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease.在炎症性肠病中，与抗肿瘤坏死因子治疗相比，vedolizumab 术后手术部位感染的风险：倾向评分匹配分析。
Aliment Pharmacol Ther. 2018 Aug;48(3):340-346. doi: 10.1111/apt.14842. Epub 2018 Jun 7.
7
Anti-TNF Therapy Is Associated With an Increased Risk of Postoperative Morbidity After Surgery for Ileocolonic Crohn Disease: Results of a Prospective Nationwide Cohort.抗 TNF 治疗与回肠结肠克罗恩病手术后术后发病率增加相关：一项前瞻性全国队列研究结果。
Ann Surg. 2018 Feb;267(2):221-228. doi: 10.1097/SLA.0000000000002017.
8
Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations.接受维得利珠单抗治疗的克罗恩病患者行大型腹部手术后的术后结局。
Aliment Pharmacol Ther. 2018 Mar;47(5):573-580. doi: 10.1111/apt.14459. Epub 2017 Dec 18.
9
Risk factors for postoperative intra-abdominal septic complications after surgery in Crohn's disease: A meta-analysis of observational studies.克罗恩病术后腹腔内感染性并发症的危险因素：观察性研究的荟萃分析。
J Crohns Colitis. 2015 Mar;9(3):293-301. doi: 10.1093/ecco-jcc/jju028. Epub 2015 Jan 8.

Which biologic agents increase perioperative complications in patients with inflammatory bowel disease?

作者信息

Park Jihye

机构信息

Department of Internal Medicine, Yonsei University College of Medicine, Seoul Korea.

Institute of Gastroenterology, Yonsei University College of Medicine, Seoul Korea.

出版信息

Intest Res. 2022 Jan;20(1):1-2. doi: 10.5217/ir.2021.00170. Epub 2022 Jan 26.

DOI:10.5217/ir.2021.00170
PMID:35135074
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8831776/
Abstract
摘要